By Barbara Obstoj-Cardwell. Editor
Among regulatory news last week, the US Food and Drug Administration on Monday advised Alnylam Pharmaceuticals of a three-month delay to its review of the New Drug Application for amyloidosis drug vutrisiran. AstraZeneca released strong results from a Phase IIb trial of its cholesterol lowerer AZD8233. Troubled US biotech bluebird bio last Tuesday announced a significant restructuring program, which would involve a 30% reduction in its workforce. US pharma giant Pfizer announced its first M&A deal this year, agreeing a $525 million bid for RSV vaccine developer ReViral. Also, Biogen reacted angrily to the US Centers for Medicare & Medicaid Services’ (CMS) decision to limit coverage of its Alzheimer’s disease drug Aduhelm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze